-
Mashup Score: 175Moderna Announces Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant | Moderna, Inc. - 2 year(s) ago
Company testing three existing COVID-19 vaccine booster candidates against the Omicron variant Company announcing a new variant-specific vaccine candidate against Omicron (mRNA-1273.529) CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 26, 2021– Moderna, Inc.
Source: Moderna, Inc.Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Moderna Announces FDA Authorization of Booster Dose of COVID-19 Vaccine in the U.S. for Adults 18 Years and Older | Moderna, Inc. - 2 year(s) ago
Authorization includes the use of Moderna’s booster dose following primary vaccination with other authorized or approved COVID-19 vaccines CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 19, 2021– Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and
Source: Moderna, Inc.Categories: Healthcare Professionals, Latest HeadlinesTweet-
BREAKING: FDA approves emergency use authorization of a booster dose of the Moderna #COVID19 vaccine to all adults >=18 who have completed a primary vaccination with any authorized or approved COVID-19 vaccine. https://t.co/kMZSlqc6QJ
-
-
Mashup Score: 4Statement on Intellectual Property | Moderna, Inc. - 2 year(s) ago
Moderna has recognized the substantial role that the NIAID has played in helping to develop Moderna’s COVID-19 vaccine by including NIAID scientists as co-inventors on published patent applications where they have made inventive contributions. Under U.S. patent law, there are strict rules for determining who should be listed as inventors on a patent. Just because…
Source: Moderna, Inc.Categories: Healthcare Professionals, Latest HeadlinesTweet-
When $MRNA subtweets that someone "twist[ed] Moderna’s good faith application of U.S. patent law into something else," are they directing that at @NIHDirector? Is that possibly a good PR strategy? https://t.co/FUfV6HHuZ2
-
-
Mashup Score: 4Moderna Provides Update on Timing of U.S. Emergency Use Authorization of its COVID-19 Vaccine for Adolescents | Moderna, Inc. - 3 year(s) ago
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Oct. 31, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today provided an update that the U.S. Food and Drug Administration (FDA) has notified the Company that it will require additional
Source: Moderna, Inc.Categories: Healthcare Professionals, Latest HeadlinesTweet-
“On Friday evening, the FDA informed Moderna that the agency requires additional time to evaluate recent international analyses of the risk of myocarditis after vaccination.” https://t.co/kZuZcG708i
-
-
Mashup Score: 0Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age | Moderna, Inc. - 3 year(s) ago
Results are the first from pivotal study in children aged six years to under 12 years Two 50 μg doses of mRNA-1273 were generally well tolerated and showed robust neutralizing antibody titers; primary immunogenicity endpoints were met Moderna plans to submit results to the U.S.
Source: Moderna, Inc.Categories: Hematologists1, Latest HeadlinesTweet-
“Safety data continues to be monitored by an independent safety monitoring committee. All participants will be monitored for 12 months after their 2nd injection to assess long-term protection and safety. These data are subject to change” Experimental eh? https://t.co/fcvFTFnLtq
-
-
Mashup Score: 32Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age | Moderna, Inc. - 3 year(s) ago
Results are the first from pivotal study in children aged six years to under 12 years Two 50 μg doses of mRNA-1273 were generally well tolerated and showed robust neutralizing antibody titers; primary immunogenicity endpoints were met Moderna plans to submit results to the U.S.
Source: Moderna, Inc.Categories: Healthcare Professionals, Latest HeadlinesTweet-
… As I’m breaking down the Pfizer data on IG … Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age. What a time. (All jokes. No competition over here.) https://t.co/fbLiofVnDK
-
-
Mashup Score: 181
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Sep. 16, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced Health Canada has approved the New Drug Submission (NDS-CV) for SPIKEVAX™ (elasomeran mRNA vaccine), which has been
Source: Moderna, Inc.Categories: Infectious Disease, Latest HeadlinesTweet-
Canada has given Moderna full approval for Spikevax, its first anywhere. Full approval still pending from @US_FDA. https://t.co/qfKBQth2Q4
-
-
Mashup Score: 2Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic | Moderna, Inc. - 3 year(s) ago
mRNA-6231 is Moderna’s first autoimmune therapeutic candidate to enter the clinic Moderna now has clinical programs in five different therapeutic areas CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug. 2, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA)
Source: Moderna, Inc.Categories: General Medicine News, Latest HeadlinesTweet-
Moderna Announces First Participant Dosed in Phase 1 Study of Its IL-2 mRNA Therapeutic https://t.co/kCrMWmRjVR
-
-
Mashup Score: 44Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine | Moderna, Inc. - 3 year(s) ago
Final blinded analysis of Phase 3 COVE study of the Moderna COVID-19 vaccine shows 93% efficacy; efficacy remains durable through six months after second dose CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug. 25, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA)
Source: Moderna, Inc.Categories: Healthcare Professionals, Latest HeadlinesTweet-
RT @megtirrell: Moderna says it's completed its FDA submission for full approval of its #covid19 vaccine: https://t.co/i2jpALkbHB
-
-
Mashup Score: 52Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine | Moderna, Inc. - 3 year(s) ago
Final blinded analysis of Phase 3 COVE study of the Moderna COVID-19 vaccine shows 93% efficacy; efficacy remains durable through six months after second dose CAMBRIDGE, Mass. –(BUSINESS WIRE)–Aug. 25, 2021– Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA)
Source: Moderna, Inc.Categories: Expert Picks, Latest HeadlinesTweet-
#Moderna announces it has completed the submission process for full licensure of its #COVID19 vaccine for individuals 18 years of age and older. Moderna has requested Priority Review designation. PR https://t.co/Qc4Ie7yfW3
-
RT @moderna_tx: We just announced our strategy to address the omicron (B.1.1.529) SARS-CoV-2 variant. Read more: https://t.co/dKzD3YFUV2 ht…